Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution - Wikidata - awgldk - TriplyDB

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

http://www.wikidata.org/entity/Q36778450

about

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice Ocrelizumab: a step forward in the evolution of B-cell therapy Signalling pathway database usability: lessons learned.The anti-inflammatory and immunomodulatory potential of braylin: Pharmacological properties and mechanisms by in silico, in vitro and in vivo approaches Vaccinations in patients with immune-mediated inflammatory diseases Interleukin expression after injury and the effects of interleukin-1 receptor antagonist A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population.The role of the lymphatic system in inflammatory-erosive arthritis.The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin Hinokitiol Negatively Regulates Immune Responses through Cell Cycle Arrest in Concanavalin A-Activated Lymphocytes.Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis Drug-induced inflammatory bowel disease and IBD-like conditions.The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Adalimumab in the treatment of immune-mediated diseases.Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.Biological nurse specialist: goodwill to good practice.The genomic landscape of human immune-mediated diseases.Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.Biosimilars for the management of rheumatoid arthritis: economic considerations.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate.Vagal influences in rheumatoid arthritis.Anti-Inflammatory Effects of Modified Adenoviral Vectors for Gene Therapy: A View through Animal Models Tested.Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Pleiotrophin, the angiogenic and mitogenic growth factor: levels in serum and synovial fluid in rheumatoid arthritis and osteoarthritis : And correlation with clinical, laboratory and radiological indices.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation.Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.The structure-function relationship of disulfide bonds in etanercept.Adherence to systemic therapies for immune-mediated inflammatory diseases in Lebanon: a physicians' survey from three medical specialties.The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis.

P2860

Q26778585-D29FE98F-82E6-4462-8993-12C4AD5A6C9D Q28085019-5D6ACB90-C213-42FE-9795-BF0944FA8233 Q28245986-AF1E9535-5F73-4673-95E6-79644CFC295A Q30486334-140DC961-42E3-4493-9FFD-3C97A69C0F97 Q33778757-70474F05-8F0B-48F0-BB10-DBBC9C300960 Q34117134-8342D0C9-B8B2-4CC7-A2BB-9D178A0A4905 Q34927037-5BB3ADE7-2576-46A7-B8D0-CEDDE7569726 Q35229490-02EF5EEE-E417-494A-B0A4-03BE6EADF128 Q35417662-B6BA13C2-D1B3-4F89-AAE8-E5F75183458C Q35969881-8DB053D7-BCF8-4D78-A835-653AD9EE857A Q36038544-30571190-F2FF-433C-A891-12008099D53E Q37143729-95EEED6B-44D6-4BA6-9434-749C0DBBF9C2 Q37538469-52E78FD9-CC26-4A09-A5F8-38EE7C0DBF37 Q37616966-D6616FF7-AFC8-4561-A42B-1B56F4EF4309 Q37735799-4C3A6E4A-1C86-4489-8F98-6931C637B899 Q38008983-AB823FA4-FCE7-4C56-A0B2-959A7952230D Q38207758-79DAB060-96F3-4DBD-AECE-1F010771A66F Q38207759-19157990-3EED-4A57-A813-96EB2CA07B14 Q38207760-191A7BB3-6F75-419A-8A52-D8247D7FCAE7 Q38375767-6E9584B6-2162-4EAB-9BDB-BE8F43BE2F5F Q38429514-EAA26C76-8573-4E22-90ED-3FE41B183D76 Q38569875-C43DFFC2-6B13-4380-AB87-804F9F7B254A Q38591275-AEED0B82-1172-4407-BE8D-B82490ADD709 Q38591281-D2594B45-82C9-4451-9021-C1AA411E4570 Q38592363-E1298E8A-C23D-465A-A5FD-FF7BA0C525AA Q38594411-3D61D193-E6EB-4E45-81E0-1FDAF7321313 Q38611360-3521EDB0-D2F5-4175-B47D-7A05D8CC248E Q38647845-A9E12579-D89D-421F-A479-D6E5A42AF7E9 Q38648179-57986F36-EFCF-4812-B834-E36B9E02C4B5 Q38849248-4DCDD8A7-9A31-4358-88CE-F1F5B33DB495 Q38979811-E6426167-8C20-4C92-BB2A-5E13DFB66C1F Q38992643-5FAFE097-2D04-4C03-8465-59960F7044AA Q39051341-7DF7FE54-E861-4E0E-A12C-08DF7E37D10A Q39140572-B9844D19-159A-4C53-B56C-C872C5E4018D Q39152159-74643459-5E01-44C8-9171-B5458AA9E658 Q39179342-DD48043E-E9BD-4B89-9D04-F8B4912E810A Q40987050-97A0E8D7-D0DF-4A90-B837-6D782AB6D5EF Q41073658-805E11CA-F995-4A90-AB2B-728F40268D82 Q41816131-B527F070-7066-4D8A-8AE9-207EE3282E9E Q41973199-2026B954-84B1-4C6F-A264-D027288776B1

P2860

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

http://www.wikidata.org/entity/Q36778450

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@ast

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@en

type

label

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@ast

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@en

prefLabel

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@ast

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@en

P1433

Q36778450-F6375AE3-9868-4460-956E-94A4C2BD1E3B

P1476

Q36778450-E9C38F44-AFF0-40A0-9B23-FE6144F96CF9

P2093

Q36778450-A64A5C28-7D5D-4931-AC51-3DC57B8E36E9

Q36778450-D6361492-F152-46CF-89A5-D442AE2012C8

Q36778450-E41DD49F-FE23-4D84-BECB-55593EDB2017

P2860

Q36778450-0018942C-6D37-4083-9D67-7A37138696C4

Q36778450-04D4F2A3-FAA4-4E52-892A-C6D9E5AD3422

Q36778450-092C23FE-BF2C-4E1A-86D5-791AC94DC80F

Q36778450-0B96D61C-2AA9-40DE-8C62-CC0B5AFA9533

Q36778450-16C787F0-956E-4DCB-B3F8-E181E197BDEA

Q36778450-1743C58A-B178-4BC6-8586-C60A1D36CB02

Q36778450-273FDD9C-A58C-4DCA-8C45-D3246571CF6F

Q36778450-28CBFF9A-EE39-4F61-938F-134F39117887

Q36778450-2EFD05DF-D2F7-4C71-B3F1-AE4E9A5F2068

Q36778450-387A514E-7263-4493-B5C7-C0334C9F7A86

P304

Q36778450-74BA9D2F-203A-4DD9-A8FE-51D5F418C599

P31

Q36778450-7D8CA011-DC90-41D2-A19E-ED51D24546C3

P356

Q36778450-8120BE5C-DB0C-4690-9BFD-0C6AC1205D42

P407

Q36778450-61111747-E06A-4229-BA08-96CFA847A36C

P433

Q36778450-E11D316D-66AE-40E8-A6D5-7497DF8C4FBE

P478

Q36778450-638D8860-AB5F-4CBA-931D-72A0A64A9CD1

P577

Q36778450-D05F5E2F-6E3E-4F15-B216-ACD3D4DFAE5C

P5875

Q36778450-38E7F6A2-DF1D-43DE-9AA8-AB0BEA1F2657

P698

Q36778450-C5370007-85E3-44C8-92C8-1470C03E44B5

P932

Q36778450-269EA293-44F3-4414-8AC9-0D1F15E8691D

P356

PGMJ.2006.052688

P1433

Postgraduate Medical Journal

P1476

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

@en

P2093

Andrew J K Ostör

http://www.w3.org/2001/XMLSchema#string

Annabel Kuek

http://www.w3.org/2001/XMLSchema#string

Brian L Hazleman

http://www.w3.org/2001/XMLSchema#string

P2860

Do self-perpetuating B lymphocytes drive human autoimmune disease?

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Radiographic changes in early rheumatoid disease.

P304

251-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/PGMJ.2006.052688

http://www.w3.org/2001/XMLSchema#string

P407

P433

978

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51385487

http://www.w3.org/2001/XMLSchema#string

P698

17403952

http://www.w3.org/2001/XMLSchema#string

P932

2600039

http://www.w3.org/2001/XMLSchema#string